All News

cost.price_.drugs_.pills_.jpg

Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective?

Jack Cush, MD

Treatment advances with new biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) have proven efficacy and safety; but does their increased cost yield commensurate benefits in patients with rheumatoid arthritis (RA) and high disease activity?

Read Article
depression oh no HA

Why Depression Screening Should be Mandatory at Each Visit

Jack Cush, MD

Depression is more widespread than ever in the United States, according to a new study from Gallup, showing that 18% of adults are depressed (or receiving depression treatment for depression) – an increase in 7 percentage points since 2015. 

Read Article
Nail, pitting, psoriasis, onycholysis

EULAR Offers Tips on Psoriasis Progression to PsA

MedPage Today

Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" documentopens in a new tab or window from the European Alliance of Associations for Rheumatology (EULAR).

Read Article
labs2.jpg

Time to Risk Stratify Methotrexate Lab Monitoring?

Jack Cush, MD

A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.

Read Article
sperm

Methotrexate - an old trusted friend who deserves better

Antoni Chan, MD, PhD

Methotrexate (MTX) has been used as the anchor drug for the treatment of RA and PsA for many years. Despite our long experience with the use of MTX, one area that has remained uncertain is its effect on male fertility. There is now increasing evidence that cessation of MTX in males prior to trying conceive is not necessary.

Read Article
Rheums! Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/3atPdJwb1m https://t.co/MKbgzEi9pd

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR Offers Tips on Psoriasis Progression to PsA Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" from the EULAR. https://t.co/eFsWJBmzCR https://t.co/slq58tWJG6

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimzelx) has been EMA approved to treat adults with active PsA & axial spondylarthritis in the EU. This dual IL-17 A/F inhibitor is approved to treat moderate -severe plaque psoriasis in the EU, Canada, UK & Japan; but not yet in USA https://t.co/DGczkgHtpZ https://t.co/TquFCuh4QG

Links:

Dr. John Cush RheumNow ( View Tweet)
Assessment of Psoriatic Arthritis: A Global Perspective Drs. Antoni Chan, Nelly Ziade and Ihsane Hmamouchi discuss POS1542 presented at EULAR 2023 in Milan, Italy. https://t.co/qkhdNDn37k https://t.co/Ux4PCxRdn8

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR Offers Tips on Psoriasis Progression to PsA Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" from the EULAR. https://t.co/JP7OjpYtBe https://t.co/HMFkzMGOFO

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimzelx) has been EMA approved to treat adults with active PsA & axial spondylarthritis in the EU. This dual IL-17 A/F inhibitor is approved to treat moderate -severe plaque psoriasis in the EU, Canada, UK & Japan; but not yet in USA https://t.co/kmjo3HYg4K https://t.co/PINZryXQBP

Links:

Dr. John Cush RheumNow ( View Tweet)
The Importance of Identifying Central Pain in PsA Dr. Eric Ruderman discusses abstracts OP0068 and OP0299 at EULAR 2023 in Milan, Italy. https://t.co/5fjNTrQvNx https://t.co/E1ivkK2bFz

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Zoster Management and Vaccination Drs. Janet Pope and Kevin Winthrop at EULAR 2023 in Milan, Italy. https://t.co/eOhXzw3Epy https://t.co/h3NoDggg5x

Links:

Dr. John Cush RheumNow ( View Tweet)
Methotrexate - an old trusted friend who deserves better MTX has been used as the anchor drug for the treatment of RA and PsA for many years. It has been co-prescribed with biologics and JAKi in clinical trials and as well as in clinical practice. https://t.co/rSHsysJQ46 https://t.co/OKfBiMlqyg

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR points to consider in the match from PSO to PSA. 5 overarching principles and 10 points to consider. The presence of synovitis in PSO could be used as an outcome for prevention trials, Zabotti A et al, Abst#OP0062 #EULAR2023 @RheumNow https://t.co/tbnuhBCjTU
Dr. Antoni Chan synovialjoints ( View Tweet)
EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
Dr. Antoni Chan synovialjoints ( View Tweet)
One new overarching principle for @eular_org PsA recommendations: “The choice of treatment should take account of safety considerations regarding individual MoA to optimize the benefit-risk profile” Wonder what triggered that #EULAR2023 #oralsurveillance @RheumNow https://t.co/19BfJQz4Za
David Liew drdavidliew ( View Tweet)
Central sensitization of neuropathic pain in #PsA - patient reported outcomes. 114 pts. And 22 percent with fibromyalgia Pts with neuropathic pain didnt reach low disease activity or remission. @RheumNow #EULAR2023 highlights! https://t.co/Gxkcrruamp
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 recommendation update summary from the 2018 in #PsA whats new! - 3 more drugs now available in PsA. – Guselkumab, Upadacitnib, Risankizumab (1 more in the pipeline) - safety now to to considered! - consider the full picture - extraarticular manifestations @rheumnow https://t.co/7GBILtCX4i
Bella Mehta bella_mehta ( View Tweet)
meds for PsA at #EULAR2023 recommendations bDMARD after csDMARD (no order proposed) @RheumNow https://t.co/bHMG4A8nmP
Bella Mehta bella_mehta ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×